Results 81 to 90 of about 18,957 (200)
ChemistrySelect, Volume 11, Issue 16, 27 April 2026.A green and sustainable protocol for the halogenation of 4‐aminocoumarins using trihaloisocyanuric acids was developed, affording compounds with the predicted potential to inhibit protein targets associated with Alzheimer's disease. ABSTRACT A highly efficient and selective protocol for the halogenation of the C─H bond of 4‐aminocoumarin derivatives is
Maryelle A. G. de Carvalho +9 more
wiley +1 more source
PLoS ONEBackground & aimsGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits.
Sung Ryul Shim +5 more
doaj +1 more source
Tyrosine-based rivastigmine-loaded organogels in the treatmant of Alzheimer's disease [PDF]
, 2010 Faculté de PharmacieOrganogels can be prepared by immobilizing an organic phase into a threedimensional network coming from the self-assembly of a low molecular weight gelator molecule.
Bastiat, Guillaume +7 more
core +4 more sources
Acta Medica Iranica, 2008 Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl ...
R. Abolfazli +1 more
doaj
Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease : a randomised controlled trial [PDF]
, 2019 Background Melatonin may reduce REM-sleep behavior disorder (RBD) symptoms in Parkinson's disease (PD), though robust clinical trials are lacking. Objective To assess the efficacy of prolonged-release (PR) melatonin for RBD in PD.
Coeytaux Jackson, Alessandra +10 more
core +1 more source
Rivastigmine in Chinese patients with subcortical vascular dementia
Neuropsychiatric Disease and Treatment, 2007 Vincent Mok1, Adrian Wong1, Simon Ho2, Thomas Leung1, Wynnie WM Lam2, Ka Sing Wong11Department of Medicine and Therapeutics; 2Department of Radiology and Organ Imaging, The Chinese University of Hong Kong, Shatin, Hong Kong, ChinaBackground: We explored ...
Vincent Mok +5 more
doaj
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm(2)) in Alzheimer’s disease [PDF]
, 2012 Aim: Determine whether patients with Alzheimer’s disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB ...
Bakchine, Serge +9 more
core +1 more source
Rivastigmine for the treatment of dementia associated with Parkinson’s disease
Neuropsychiatric Disease and Treatment, 2007 Jennifer L Reingold, John C Morgan, Kapil D SethiMovement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA, USAAbstract: Parkinson’s disease (PD) afflicts millions of people worldwide and leads to cognitive ...
Jennifer L Reingold +2 more
doaj
Effect of Pharmacological Interventions on the Fronto-Cingulo-Parietal Cognitive Control Network in Psychiatric Disorders: A Transdiagnostic Systematic Review of fMRI Studies [PDF]
, 2016 Executive function deficits such as working memory, decision-making, and attention problems are a common feature of several psychiatric disorders for which no satisfactory treatment exists.
Dennis Hernaus, Thérèse van Amelsvoort
core +2 more sources
Behavioural Neurology, 1999 Alzheimer’s disease (AD) is accompanied by prominent behavioural disturbances. They cause significant distress for both caregivers and patients and can play a major role in the decision to institutionalise AD patients.
Michael Rösler +3 more
doaj +1 more source